FASLG and COVID-19: In light of this evidence and our findings, COVID-19 may induce an antiphospholipid-like condition that plays a role in increasing the severity of disease manifestation; this hypothesis is strongly supported by the findings of Laura et al., who examined 106 COVID-19 patients for the presence of aPL antibodies, including 30 hospitalized cases, 47 hospitalized nonneurological COVID-19 controls, and 29 COVID-19 nonhospitalized controls, and reported a high prevalence of antiphospholipid antibodies in 72 (67.9%) of all cases and 22 (73.3%) of the 30 hospitalized neurological cases [33].